Beta45% was sold under disclosed trading plans, 48% to cover taxes, 7% with no plan disclosed. The largest seller, Christopher Anzalone (Chief Executive Officer, Director), sold $24.0M.Share-of-stake figures for this company are being verified and will be added when that check is finished. Why
A share of stake is shown for 0 of the 10 officers and directors who sold. 12 are left out Disclosed company stock is not an insider's whole wealth.i
Left out: Christopher Anzalone, Patrick O'Brien, James Hamilton, Michael Perry, Mauro Ferrari, William Waddill, Hongbo Lu, Douglas Ingram, Victoria Vakiener, Adeoye Olukotun, Daniel Apel and Matthew Cohen (share of stake is being verified).
Officers and directors, past 12 months. Their share of stake is being verified and is not shown yet; amounts and trading plans are below.
Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.
No officer or director trades were reported for the past 30 days. The most recent before that:
| Who | Shares | Price | % of total stake | Total stake after | Trade date | Filed |
|---|---|---|---|---|---|---|
| Michael Perry Director | 11,600 | $87.30 | n/a | n/a | Aug 18, 2026 | Aug 20, 2026 |
| Adeoye Olukotun Director | 2,000 | $86.96 | n/a | n/a | Aug 18, 2026 | Aug 20, 2026 |
Yes. Christopher Anzalone sold 360K shares ($24.0M) in the past 12 months, 26% of it under a trading plan disclosed in the filings.
Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 45% of sales by value ran under 10b5-1 trading plans disclosed in the filings, 48% were to cover taxes and 7% had no disclosed plan. A trading plan schedules sales in advance.
No. Officers and directors reported no purchases in the past 12 months.
| Who sold | Amount | % of holdings | Trading plan |
|---|---|---|---|
| Christopher Anzalone Chief Executive Officer, Director | $24.0M 360K shares | Not confirmedshare of stake is being verified. Why | 26% under a disclosed plan, 74% to cover taxes |
| James Hamilton Chief Medical Officer | $3.9M 60K shares | Not confirmedshare of stake is being verified. Why | Disclosed plan |
| Patrick O'Brien COO | $3.1M 49K shares | Not confirmedshare of stake is being verified. Why | Disclosed plan |
| Michael Perry Director | $2.0M 28K shares | Not confirmedshare of stake is being verified. Why | No plan disclosed |
| Mauro Ferrari Director | $1.0M 16K shares | Not confirmedshare of stake is being verified. Why | 52% under a disclosed plan 48% no plan disclosed |
| Daniel Apel Chief Financial Officer | $934K 13K shares | Not confirmedshare of stake is being verified. Why | Disclosed plan |
| Adeoye Olukotun Director | $851K 12K shares | Not confirmedshare of stake is being verified. Why | 80% under a disclosed plan 20% no plan disclosed |
| Victoria Vakiener Director | $679K 10K shares | Not confirmedshare of stake is being verified. Why | Disclosed plan |
| William Waddill Director | $566K 8.4K shares | Not confirmedshare of stake is being verified. Why | Disclosed plan |
| Hongbo Lu Director | $228K 3K shares | Not confirmedshare of stake is being verified. Why | Disclosed plan |
Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.
| Insider | Held Oct 16, 2025 | Sold | Held Oct 16, 2026 | Still held | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Christopher Anzalone!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Christopher Anzalone are complete. Chief Executive Officer, Director | n/a | −360K | n/a | n/a | ||||||||||||
Vesting, gifts, unvested awards and holding lines for Christopher AnzaloneHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Christopher Anzalone are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($86.96 − strike price), using the most recent insider trade price on Form 4 (Aug 18, 2026), not a market close. | ||||||||||||||||
Patrick O'Brien!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Patrick O'Brien are complete. COO | n/a | −49K | n/a | n/a | ||||||||||||
Vesting, gifts, unvested awards and holding lines for Patrick O'BrienHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Patrick O'Brien are complete; balances and unit counts will be added when the check is finished. −5.3Kgifted (net of own trusts) | ||||||||||||||||
James Hamilton!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for James Hamilton are complete. Chief Medical Officer | n/a | −60K | n/a | n/a | ||||||||||||
Vesting, gifts, unvested awards and holding lines for James HamiltonHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for James Hamilton are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) | ||||||||||||||||
Michael Perry!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Michael Perry are complete. Director | n/a | −28K | n/a | n/a | ||||||||||||
Vesting, gifts, unvested awards and holding lines for Michael PerryHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Michael Perry are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) | ||||||||||||||||
Mauro Ferrari!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Mauro Ferrari are complete. Director | n/a | −16K | n/a | n/a | ||||||||||||
Vesting, gifts, unvested awards and holding lines for Mauro FerrariHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Mauro Ferrari are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) | ||||||||||||||||
William Waddill!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for William Waddill are complete. Director | n/a | −8.4K | n/a | n/a | ||||||||||||
Vesting, gifts, unvested awards and holding lines for William WaddillHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for William Waddill are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) | ||||||||||||||||
Hongbo Lu!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Hongbo Lu are complete. Director | n/a | −3K | n/a | n/a | ||||||||||||
Vesting, gifts, unvested awards and holding lines for Hongbo LuHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Hongbo Lu are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) | ||||||||||||||||
Douglas Ingram!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Douglas Ingram are complete. Director | n/a | 0 | n/a | n/a | ||||||||||||
Vesting, gifts, unvested awards and holding lines for Douglas IngramHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Douglas Ingram are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) | ||||||||||||||||
Victoria Vakiener!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Victoria Vakiener are complete. Director | n/a | −10K | n/a | n/a | ||||||||||||
Vesting, gifts, unvested awards and holding lines for Victoria VakienerHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Victoria Vakiener are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) | ||||||||||||||||
Adeoye Olukotun!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Adeoye Olukotun are complete. Director | n/a | −12K | n/a | n/a | ||||||||||||
Vesting, gifts, unvested awards and holding lines for Adeoye OlukotunHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Adeoye Olukotun are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) | ||||||||||||||||
Daniel Apel!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Daniel Apel are complete. Chief Financial Officer | n/a | −13K | n/a | n/a | ||||||||||||
Vesting, gifts, unvested awards and holding lines for Daniel ApelHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Daniel Apel are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) | ||||||||||||||||
Matthew Cohen!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Matthew Cohen are complete. Director | n/a | 0 | n/a | n/a | ||||||||||||
Vesting, gifts, unvested awards and holding lines for Matthew CohenHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Matthew Cohen are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) | ||||||||||||||||
Holdings and share of stake for Arrowhead Pharmaceuticals, Inc. are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.
Officer and director open-market sales: $37.3M across 560,501 shares. Plan status and stated purpose are separate questions, and a sale can have both.
The lighter segment is sales with no plan disclosed in the filing ($20.5M), including tax-related sales outside a plan.
Sales with no 10b5-1 plan and no tax reference in the filing. $2.0M of it is Michael Perry. No plan disclosed is a statement about the filing, not about why the sale happened. Largest such sale: Michael Perry, Aug 18, 2026
$24.6M of sales (66.0%) cite tax obligations in their footnotes, $6.8M of them also under a plan. Example: Daniel Apel, Apr 22, 2026
| Seller | Shares sold | Proceeds | Under a disclosed plan | Share of total | Sales dates |
|---|---|---|---|---|---|
| Christopher Anzalone Chief Executive Officer, Director | 360K | $24.0M | 26% | 64% | Dec 15, 2025 to Jan 2, 2026 |
| James Hamilton Chief Medical Officer | 60K | $3.9M | 100% | 11% | Jan 5, 2026 to Apr 23, 2026 |
| Patrick O'Brien COO | 49K | $3.1M | 100% | 8% | Jan 5, 2026 to Jan 5, 2026 |
| Michael Perry Director | 28K | $2.0M | 0% | 5% | Dec 5, 2025 to Aug 18, 2026 |
| Mauro Ferrari Director | 16K | $1.0M | 52% | 3% | Nov 28, 2025 to Dec 26, 2025 |
| Daniel Apel Chief Financial Officer | 13K | $934K | 100% | 3% | Apr 22, 2026 to Apr 22, 2026 |
| Adeoye Olukotun Director | 12K | $851K | 80% | 2% | Dec 19, 2025 to Aug 18, 2026 |
| Victoria Vakiener Director | 10K | $679K | 100% | 2% | Dec 19, 2025 to Dec 19, 2025 |
| William Waddill Director | 8.4K | $566K | 100% | 2% | Dec 19, 2025 to Dec 19, 2025 |
| Hongbo Lu Director | 3K | $228K | 100% | 0.6% | May 12, 2026 to May 12, 2026 |
| Month | Sale proceeds | Disclosed plan | To cover taxes | No plan disclosed |
|---|---|---|---|---|
| Oct 2025 | $0 | $0 | $0 | $0 |
| Nov 2025 | $493K | $0 | $0 | $493K |
| Dec 2025 | $26.6M | $7.8M | $17.8M | $992K |
| Jan 2026 | $6.5M | $6.5M | $0 | $0 |
| Feb 2026 | $0 | $0 | $0 | $0 |
| Mar 2026 | $642K | $642K | $0 | $0 |
| Apr 2026 | $1.7M | $1.7M | $0 | $0 |
| May 2026 | $228K | $228K | $0 | $0 |
| Jun 2026 | $0 | $0 | $0 | $0 |
| Jul 2026 | $0 | $0 | $0 | $0 |
| Aug 2026 | $1.2M | $0 | $0 | $1.2M |
| Sep 2026 | $0 | $0 | $0 | $0 |
| Oct 2026 | $0 | $0 | $0 | $0 |
In line with the past 5 years. 10 insiders sold; the average is 10 a year.
| 12 months ending | Shares sold | Insiders who sold | Proceeds |
|---|---|---|---|
| Oct 16, 2026 Latest 12 months | 561K | 10 | $37.3M |
| Oct 16, 2025 1 year earlier | 744K | 8 | $13.2M |
| Oct 16, 2024 2 years earlier | 299K | 10 | $9.7M |
| Oct 17, 2023 3 years earlier | 320K | 10 | $11.5M |
| Oct 17, 2022 4 years earlier | 410K | 10 | $24.8M |
| Oct 17, 2021 5 years earlier | 553K | 12 | $39.6M |
Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.
Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for Arrowhead Pharmaceuticals, Inc. are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.
External context: we only cite outside events when a documented connection exists. None is shown for this period.
All 497 Forms 3, 4 and 5 on record for Arrowhead Pharmaceuticals, Inc. (SEC CIK 879407), filed from Feb 3, 2004 to Aug 20, 2026; 31 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 16, 2026. Prices are the ones reported in each filing, often weighted averages.
Probable 1-for-10 stock split on or before Oct 9, 2013 (first filing that shows post-split balances). Splits aren't reported as transactions; 4 holding lines changed by exactly this ratio, so earlier share counts are restated.
Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.
Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".
Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.